Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Australian Court Orders Biota Dispute With GSK To Mediation (Australia)

This article was originally published in PharmAsia News

Executive Summary

An Australian judge ordered Biota Holdings to mediation in its dispute with GlaxoSmithKline over the marketing of the flu drug Relenza (zanamivir). Biota accused GSK in a court suit of not properly promoting the drug Biota developed and GSK licensed. The judge ordered mediation to be completed by May 16, 2008. Biota sued GSK in Australia for as much as $606 million, U.S., noting the drug's sales were overshadowed by Roche Holding's Tamiflu. (Click here for more

Table

View full table

Tags:
Latest Headlines

Obesity Gold Rush To Drive Significant Spending Growth Through Decade, IQVIA Says

With Vertex Pain Drug Filed At FDA, Commercial Ramp Is Under Way

Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024

See All
UsernamePublicRestriction

Register

SC065880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By